Literature DB >> 18052103

Progress and challenges in selected areas of tobacco carcinogenesis.

Stephen S Hecht1.   

Abstract

Tobacco use continues to be a major cause of cancer in the developed world, and despite significant progress in this country in tobacco control, which is driving a decrease in cancer mortality, there are still over 1 billion smokers in the world. This perspective discusses some selected issues in tobacco carcinogenesis focusing on progress during the 20 years of publication of Chemical Research in Toxicology. The topics covered include metabolism and DNA modification by tobacco-specific nitrosamines, tobacco carcinogen biomarkers, an unidentified DNA ethylating agent in cigarette smoke, mutations in the K-RAS and p53 gene in tobacco-induced lung cancer and their possible relationship to specific carcinogens, secondhand smoke and lung cancer, emerging issues in smokeless tobacco use, and a conceptual model for understanding tobacco carcinogenesis. It is hoped that a better understanding of mechanisms of tobacco-induced cancer will lead to new and useful approaches for the prevention of lung cancer and other cancers caused by tobacco use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052103      PMCID: PMC2556958          DOI: 10.1021/tx7002068

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  120 in total

Review 1.  Site-specific mutagenesis: retrospective and prospective.

Authors:  B Singer; J M Essigmann
Journal:  Carcinogenesis       Date:  1991-06       Impact factor: 4.944

2.  Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats.

Authors:  M A Morse; K I Eklind; M Toussaint; S G Amin; F L Chung
Journal:  Carcinogenesis       Date:  1990-10       Impact factor: 4.944

3.  Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites.

Authors:  S S Hecht; N Trushin; C A Reid-Quinn; E S Burak; A B Jones; J L Southers; C T Gombar; S G Carmella; L M Anderson; J M Rice
Journal:  Carcinogenesis       Date:  1993-02       Impact factor: 4.944

4.  K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung.

Authors:  W H Westra; R J Slebos; G J Offerhaus; S N Goodman; S G Evers; T W Kensler; F B Askin; S Rodenhuis; R H Hruban
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

5.  Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers.

Authors:  P G Foiles; S A Akerkar; S G Carmella; M Kagan; G D Stoner; J H Resau; S S Hecht
Journal:  Chem Res Toxicol       Date:  1991 May-Jun       Impact factor: 3.739

6.  O6-methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung.

Authors:  L A Peterson; S S Hecht
Journal:  Cancer Res       Date:  1991-10-15       Impact factor: 12.701

7.  Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine.

Authors:  S G Carmella; S Akerkar; S S Hecht
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

8.  Evidence supporting the role of DNA pyridyloxobutylation in rat nasal carcinogenesis by tobacco-specific nitrosamines.

Authors:  N Trushin; A Rivenson; S S Hecht
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents.

Authors:  Z A Ronai; S Gradia; L A Peterson; S S Hecht
Journal:  Carcinogenesis       Date:  1993-11       Impact factor: 4.944

View more
  96 in total

1.  Urinary Biomarkers of Carcinogenic Exposure among Cigarette, Waterpipe, and Smokeless Tobacco Users and Never Users of Tobacco in the Golestan Cohort Study.

Authors:  Arash Etemadi; Hossein Poustchi; Cindy M Chang; Benjamin C Blount; Antonia M Calafat; Lanqing Wang; Victor R De Jesus; Akram Pourshams; Ramin Shakeri; Meredith S Shiels; Maki Inoue-Choi; Bridget K Ambrose; Carol H Christensen; Baoguang Wang; Gwen Murphy; Xiaoyun Ye; Deepak Bhandari; Jun Feng; Baoyun Xia; Connie S Sosnoff; Farin Kamangar; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Christian C Abnet; Reza Malekzadeh; Neal D Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-08       Impact factor: 4.254

2.  Oral Dosing of Dihydromethysticin Ahead of Tobacco Carcinogen NNK Effectively Prevents Lung Tumorigenesis in A/J Mice.

Authors:  Qi Hu; Pedro Corral; Sreekanth C Narayanapillai; Pablo Leitzman; Pramod Upadhyaya; M Gerard O'Sullivan; Stephen S Hecht; Junxuan Lu; Chengguo Xing
Journal:  Chem Res Toxicol       Date:  2020-06-11       Impact factor: 3.739

3.  The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.

Authors:  Rachel I Vogel; Steven G Carmella; Irina Stepanov; Dorothy K Hatsukami; Stephen S Hecht
Journal:  Biomarkers       Date:  2011-08-03       Impact factor: 2.658

Review 4.  DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans.

Authors:  Byeong Hwa Yun; Jingshu Guo; Medjda Bellamri; Robert J Turesky
Journal:  Mass Spectrom Rev       Date:  2018-06-11       Impact factor: 10.946

5.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

Authors:  Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale
Journal:  J Natl Cancer Inst       Date:  2011-07-11       Impact factor: 13.506

6.  Urinary biomarkers for secondhand smoke.

Authors:  Toshihiro Ino; Tetsuya Ohtani; Itsuro Yoshimi
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

7.  Clinical Trial of 2-Phenethyl Isothiocyanate as an Inhibitor of Metabolic Activation of a Tobacco-Specific Lung Carcinogen in Cigarette Smokers.

Authors:  Jian-Min Yuan; Irina Stepanov; Sharon E Murphy; Renwei Wang; Sharon Allen; Joni Jensen; Lori Strayer; Jennifer Adams-Haduch; Pramod Upadhyaya; Chap Le; Mindy S Kurzer; Heather H Nelson; Mimi C Yu; Dorothy Hatsukami; Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-07

8.  Identification of adducts formed in the reactions of 5'-acetoxy-N'-nitrosonornicotine with deoxyadenosine, thymidine, and DNA.

Authors:  Pramod Upadhyaya; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2008-11       Impact factor: 3.739

Review 9.  Biomarkers of induced active and passive smoking damage.

Authors:  Maura Lodovici; Elisabetta Bigagli
Journal:  Int J Environ Res Public Health       Date:  2009-02-26       Impact factor: 3.390

10.  A small-cell lung cancer genome with complex signatures of tobacco exposure.

Authors:  Erin D Pleasance; Philip J Stephens; Sarah O'Meara; David J McBride; Alison Meynert; David Jones; Meng-Lay Lin; David Beare; King Wai Lau; Chris Greenman; Ignacio Varela; Serena Nik-Zainal; Helen R Davies; Gonzalo R Ordoñez; Laura J Mudie; Calli Latimer; Sarah Edkins; Lucy Stebbings; Lina Chen; Mingming Jia; Catherine Leroy; John Marshall; Andrew Menzies; Adam Butler; Jon W Teague; Jonathon Mangion; Yongming A Sun; Stephen F McLaughlin; Heather E Peckham; Eric F Tsung; Gina L Costa; Clarence C Lee; John D Minna; Adi Gazdar; Ewan Birney; Michael D Rhodes; Kevin J McKernan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.